VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 10, 2006) - WEX Pharmaceuticals Inc. (“WEX” or the “Company”) (TSX:WXI) is pleased to announce that the Company has signed the term sheet of the license agreement with Children’s Hospital Boston, for the development and commercialization of pharmaceutical(s) containing Tetrodotoxin (TTX) for prolonged local anesthesia based on the patented technology by Children’s Hospital. Preliminary data suggests that the new product could have much longer anesthetic effect than products currently on the market and reduce the amount of pain the patients may suffer after surgery.
